edd/Vaccine

Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries.Cutland CL Gutu K Yun JA Izu A Mahtab S Peter J Ansah NA Obaro S Tilahun B Jambo K Sow S Kagucia EW Chicumbe S Dlamini T Browne M Clothier H Griffin J Jiang Y Lee A Ghebreab L Madhi SA Black SB Active vaccine safety surveillance team
Vaccine, (2025). 62:127441

Seroprevalence of Immunoglobulin G against measles and rubella over a 12-year period (2009-2021) in Kilifi, Kenya and the impact of the Measles-Rubella (MR) vaccine campaign of 2016.Mburu CN Ojal J Selim R Ombati R Akech D Karia B Tuju J Sigilai A Smits G van Gageldonk PGM van der Klis FRM Flasche S Kagucia EW Scott JAG Adetifa IMO
Vaccine, (2025). 61:127425

Uptake and determinants of routine immunization among vulnerable children and adolescents in sub-Saharan Africa: A scoping review.Chege CK Karanja S Ogallo W Were F van Hensbroek MB Agweyu A
Vaccine, (2025). 54:127021

The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.Lucinde RK Karia B Ouma N Amadi D Nyundo C Mataza C Nyaguara A Scott JAG Gallagher KE Kagucia E
Vaccine, (2023). 41:666-675

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.Sparrow E Adetifa I Chaiyakunapruk N Cherian T Fell DB Graham BS Innis B Kaslow DC Karron RA Nair H Neuzil KM Saha S Smith PG Srikantiah P Were F Zar HJ Feikin D
Vaccine, (2022). 40:3506-3510

Unmet need for COVID-19 vaccination coverage in Kenya.Muchiri SK Muthee R Kiarie H Sitienei J Agweyu A Atkinson PM Edson Utazi C Tatem AJ Alegana VA
Vaccine, (2022). 40:2011-2019

Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya.Adetifa IMO Karia B Mutuku A Bwanaali T Makumi A Wafula J Chome M Mwatsuma P Bauni E Hammitt LL Mataza C Tabu C Kamau T Williams TN Scott JAG
Vaccine, (2018). 36:7965-7974

Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data.Ojal J Flasche S Hammitt LL Akech D Kiti MC Kamau T Adetifa I Nurhonen M Scott JAG Auranen K
Vaccine, (2017). 35:4561-4568

Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls.Verani JR Baqui AH Broome CV Cherian T Cohen C Farrar JL Feikin DR Groome MJ Hajjeh RA Johnson HL Madhi SA Mulholland K O'Brien KL Parashar UD Patel MM Rodrigues LC Santosham M Scott JA Smith PG Sommerfelt H Tate JE Victor JC Whitney CG Zaidi AK Zell ER
Vaccine, (2017). 35:3295-3302

Case-control vaccine effectiveness studies: Data collection, analysis and reporting results.Verani JR Baqui AH Broome CV Cherian T Cohen C Farrar JL Feikin DR Groome MJ Hajjeh RA Johnson HL Madhi SA Mulholland K O'Brien KL Parashar UD Patel MM Rodrigues LC Santosham M Scott JA Smith PG Sommerfelt H Tate JE Victor JC Whitney CG Zaidi AK Zell ER
Vaccine, (2017). 35:3303-3308

Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.Pan-Ngum W Kinyanjui T Kiti M Taylor S Toussaint JF Saralamba S Van Effelterre T Nokes DJ White LJ
Vaccine, (2017). 35:403-409

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.Nyiro JU Sande C Mutunga M Kiyuka PK Munywoki PK Scott JA Nokes DJ
Vaccine, (2015). 33:1797-801

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.Sande CJ Cane PA Nokes DJ
Vaccine, (2014). 32:4726-9

Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group.Satzke C Turner P Virolainen-Julkunen A Adrian PV Antonio M Hare KM Henao-Restrepo AM Leach AJ Klugman KP Porter BD Sa-Leao R Scott JA Nohynek H O'Brien KL WHOPneumococcal Carriage Working Group
Vaccine, (2013). 32:165-79

Strategic priorities for respiratory syncytial virus (RSV) vaccine development.Anderson LJ Dormitzer PR Nokes DJ Rappuoli R Roca A Graham BS
Vaccine, (2013). 31 Suppl 2:B209-15

Spatial and socio-demographic predictors of time-to-immunization in a rural area in Kenya: Is equity attainable?.Moisi JC Kabuka J Mitingi D Levine OS Scott JA
Vaccine, (2010). 28:5725-30

Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.Wilson JN Nokes DJ Medley GF Shouval D
Vaccine, (2007). 25:3705-12

The preventable burden of pneumococcal disease in the developing world.Scott JA
Vaccine, (2007). 25:2398-405

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.Polley SD Conway DJ Cavanagh DR McBride JS Lowe BS Williams TN Mwangi TW Marsh K
Vaccine, (2006). 24:4233-46

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.Polley SD Mwangi T Kocken CH Thomas AW Dutta S Lanar DE Remarque E Ross A Williams TN Mwambingu G Lowe B Conway DJ Marsh K
Vaccine, (2004). 23:718-28